10-Q: Green Planet Bioengineering Reports Minimal Activity in Q1 2024, Relies on Related Party Funding

Green Planet Bioengineering Co., Ltd. reports no active business operations and a net loss of $6,465 for the quarter ended March 31, 2024, relying on funding from a related party.

Summary

• Green Planet Bioengineering Co., Ltd. filed its quarterly report on Form 10-Q for the period ended March 31, 2024.
• The company operates as a public reorganized shell corporation with the purpose of acquiring or merging with an existing business operation.
• For the three months ended March 31, 2024, the company had no active business operations.
• The company reported a net loss of $6,465 for the quarter, compared to a net loss of $17,840 for the same period in 2023.
• Administrative expenses were $6,465 for the quarter, down from $17,840 in the prior year.
• The company's ability to continue as a going concern is dependent on continued support from a related party of the majority stockholder.
• As of March 31, 2024, the company had a working capital deficit of $436,055 and an accumulated deficit of $1,065,675.
• The amount due to a related party was $432,555 as of March 31, 2024.
• There were 20,006,402 common shares outstanding as of May 9, 2024.
• The company did not issue any shares of common stock or warrants during the three months ended March 31, 2024.
• The related party advanced the company $6,611 from April 1, 2024 through the date of filing.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the lack of business operations, reliance on related-party funding, and the going concern uncertainty. However, the decrease in net loss and administrative expenses provides a slight offset.

Positives

• The net loss decreased from $17,840 in Q1 2023 to $6,465 in Q1 2024, indicating a reduction in expenses.
• Administrative expenses decreased from $17,840 in Q1 2023 to $6,465 in Q1 2024.

Negatives

• The company has no active business operations.
• The company has a working capital deficit of $436,055.
• The company has an accumulated deficit of $1,065,675.
• The company is dependent on a related party for funding, raising concerns about its long-term viability.

Risks

• The company's ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.
• The company's ability to continue as a going concern is dependent on continued support from a related party, which gives rise to substantial doubt about its ability to continue operating for the next twelve months.
• If the company cannot identify funding or profitable business opportunities in the near term, it will experience delays in effecting its business plans.

Future Outlook

The company will continue to source adequate funding from future investors to execute business opportunities when they arise, but such funding and opportunities will rely entirely on prevailing circumstances.

Management Comments

• Management believes that the financial statements fairly present the company's financial position.
• Management states that the company's ability to continue as a going concern is dependent on continued support from a related party.

Industry Context

As a public reorganized shell corporation, Green Planet Bioengineering's situation is not uncommon, as many such entities seek viable business combinations. The lack of current operations and reliance on related-party funding highlight the speculative nature of the investment.

Comparison to Industry Standards

• It is difficult to compare Green Planet Bioengineering to industry standards due to its status as a shell corporation with no active business operations.
• Companies in a similar situation often have limited financial activity and rely on external funding to maintain their public listing.
• Comparisons could be made to other shell corporations or special purpose acquisition companies (SPACs) in terms of their search for acquisition targets and their financial structures, but these comparisons would be limited due to the unique circumstances of each company.

Related Party Transactions

• The company relies on a related party of the majority stockholder to advance funds to finance its operating expenses.
• The amounts advanced of $432,555 are interest-free, unsecured and are repayable upon demand.
• The related party advanced the company $6,611 from April 1, 2024 through the date of filing.

Stakeholder Impact

• Shareholders face significant risk due to the company's lack of operations and reliance on related-party funding.
• Employees (if any) are likely limited to management and their roles are dependent on the company's ability to secure funding and identify a viable business opportunity.
• Creditors (primarily the related party) are exposed to risk due to the company's financial condition and uncertainty about its ability to repay debts.

Next Steps

• The company will continue to seek adequate funding from future investors.
• The company will continue to look for business opportunities to acquire or merge with.

Key Dates

Keywords

bioengineering, shell corporation, financial results, going concern, related party, deficit, 10-Q, funding, acquisition, merger